Hiroshi Mitsumoto

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. doi request reprint Emerging drugs for amyotrophic lateral sclerosis
    Ali Aamer Habib
    The Neurological Institute of Columbia University, Eleanor and Lou Gehrig MDA ALS Center, NY 10032, USA
    Expert Opin Emerg Drugs 16:537-58. 2011
  2. ncbi request reprint Oxidative stress biomarkers in sporadic ALS
    Hiroshi Mitsumoto
    Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University Medical Center, New York, NY 10032, USA
    Amyotroph Lateral Scler 9:177-83. 2008
  3. ncbi request reprint Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction
    H Mitsumoto
    Elenor and Lou Gehrig MDA ALS Research Center, The Neurologic Institute, Columbia University, New York 10032, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 4:177-85. 2003
  4. ncbi request reprint Effects of cardiotrophin-1 (CT-1) in a mouse motor neuron disease
    H Mitsumoto
    Department of Neurology and Neurosciences, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Muscle Nerve 24:769-77. 2001
  5. ncbi request reprint Promoting excellence in end-of-life care in ALS
    Hiroshi Mitsumoto
    The Elenor and Lou Gehrig MDA ALS Research Center, Columbia University Neurological Institute, New York, NY 10032, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 6:145-54. 2005
  6. pmc How common is depression among ALS caregivers? A longitudinal study
    Judith G Rabkin
    Department of Psychiatry, New York State Psychiatric Institute, New York, NY 10032, USA
    Amyotroph Lateral Scler 10:448-55. 2009
  7. doi request reprint A prospective cohort study of neuropsychological test performance in ALS
    Paul H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Amyotroph Lateral Scler 11:312-20. 2010
  8. ncbi request reprint Outcome measures for early phase clinical trials
    Paul H Gordon
    Department of Neurology, The Eleanor and Lou Gehrig MDA ALS Research Center, College of Physicians and Surgeons, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    Amyotroph Lateral Scler 8:270-3. 2007
  9. ncbi request reprint Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis
    Edward J Kasarskis
    Department of Neurology EJK, the Graduate Center for Nutrition EJK, and the Graduate Center for Toxicology EJK the Department of Biostatistics, College of Public Health MSM the Sanders Brown Center on Aging MSM and RJK and the Department of Statistics, College of Arts and Science RJK, University of Kentucky, Lexington, KY Neurology Service, Lexington VA Medical Center, Lexington, KY EJK the Departments of Chemistry and Medicine DEM and Neurology RT, University of Vermont, Burlington, VT the Department of Neurology, Columbia University, New York, NY HM the Department of Neurology, Pennsylvania State University, Hershey, PA ZS and the Department of Neurology, University of Utah, Salt Lake City, UT MBB
    Am J Clin Nutr 99:792-803. 2014
  10. ncbi request reprint Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
    Paul H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Lancet Neurol 6:1045-53. 2007

Research Grants

Detail Information

Publications86

  1. doi request reprint Emerging drugs for amyotrophic lateral sclerosis
    Ali Aamer Habib
    The Neurological Institute of Columbia University, Eleanor and Lou Gehrig MDA ALS Center, NY 10032, USA
    Expert Opin Emerg Drugs 16:537-58. 2011
    ..While significant advances have been made in the symptomatic management of the disease, more effective drug therapy targeting disease progression is sorely needed...
  2. ncbi request reprint Oxidative stress biomarkers in sporadic ALS
    Hiroshi Mitsumoto
    Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University Medical Center, New York, NY 10032, USA
    Amyotroph Lateral Scler 9:177-83. 2008
    ..ELISA may be reliable and thus useful in epidemiology studies requiring large numbers of samples to determine the significance of increased oxidative stress markers in SALS. Further studies are required...
  3. ncbi request reprint Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction
    H Mitsumoto
    Elenor and Lou Gehrig MDA ALS Research Center, The Neurologic Institute, Columbia University, New York 10032, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 4:177-85. 2003
    ..To compare characteristics of ALS patients with and without percutaneous endoscopic gastrostomy (PEG)...
  4. ncbi request reprint Effects of cardiotrophin-1 (CT-1) in a mouse motor neuron disease
    H Mitsumoto
    Department of Neurology and Neurosciences, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Muscle Nerve 24:769-77. 2001
    ..01). We conclude that CT-1 exerts myotrophic effects as well as neurotrophic effects in a mouse model of spontaneous MND, a finding that has potential therapeutic implications for human MND...
  5. ncbi request reprint Promoting excellence in end-of-life care in ALS
    Hiroshi Mitsumoto
    The Elenor and Lou Gehrig MDA ALS Research Center, Columbia University Neurological Institute, New York, NY 10032, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 6:145-54. 2005
    ..Several public policy changes that will improve coverage for medical care, hospice, and caregiver costs are also reviewed. More clinical evidence is needed on how to provide optimal end-of-life care specifically in ALS...
  6. pmc How common is depression among ALS caregivers? A longitudinal study
    Judith G Rabkin
    Department of Psychiatry, New York State Psychiatric Institute, New York, NY 10032, USA
    Amyotroph Lateral Scler 10:448-55. 2009
    ..The high baseline rate of depression among caregivers of patients who planned tracheostomy decreased as caregivers instituted major changes in patient care or personal counseling...
  7. doi request reprint A prospective cohort study of neuropsychological test performance in ALS
    Paul H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Amyotroph Lateral Scler 11:312-20. 2010
    ..The strongest neuropsychological predictors of cognitive status were measures of executive, episodic memory and language function. Cognitively impaired patients had shorter survival time...
  8. ncbi request reprint Outcome measures for early phase clinical trials
    Paul H Gordon
    Department of Neurology, The Eleanor and Lou Gehrig MDA ALS Research Center, College of Physicians and Surgeons, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    Amyotroph Lateral Scler 8:270-3. 2007
    ..The ALSFRS-R most strongly predicted survival and provided the most complete data, but large changes may be necessary before patients perceive treatment effects...
  9. ncbi request reprint Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis
    Edward J Kasarskis
    Department of Neurology EJK, the Graduate Center for Nutrition EJK, and the Graduate Center for Toxicology EJK the Department of Biostatistics, College of Public Health MSM the Sanders Brown Center on Aging MSM and RJK and the Department of Statistics, College of Arts and Science RJK, University of Kentucky, Lexington, KY Neurology Service, Lexington VA Medical Center, Lexington, KY EJK the Departments of Chemistry and Medicine DEM and Neurology RT, University of Vermont, Burlington, VT the Department of Neurology, Columbia University, New York, NY HM the Department of Neurology, Pennsylvania State University, Hershey, PA ZS and the Department of Neurology, University of Utah, Salt Lake City, UT MBB
    Am J Clin Nutr 99:792-803. 2014
    ..Methods to estimate energy requirements have not been devised for this patient group...
  10. ncbi request reprint Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
    Paul H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Lancet Neurol 6:1045-53. 2007
    ..Several trials are planned or are in progress to assess whether minocycline slows human neurodegeneration. We aimed to test the efficacy of minocycline as a treatment for amyotrophic lateral sclerosis (ALS)...
  11. ncbi request reprint Identification of a novel D109Y mutation in Cu/Zn superoxide dismutase (sod1) gene associated with amyotrophic lateral sclerosis
    Ali Naini
    H Houston Merritt Center, Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA
    J Neurol Sci 254:17-21. 2007
    ..This amino acid change in the protein however, did not alter the catalytic activity of the SOD1 enzyme as there was no change in the enzymatic activity of purified SOD1 from the patient's erythrocytes compared to control...
  12. doi request reprint Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS
    P H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Neurology 72:1948-52. 2009
    ..To determine how clinical features at the first evaluation and in follow-up can be used to suggest a diagnostic outcome for patients with only upper motor neuron (UMN) signs at disease onset...
  13. doi request reprint A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS
    Paul H Gordon
    Department of Neurology, Columbia University, New York, USA
    Amyotroph Lateral Scler 9:212-22. 2008
    ..This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents...
  14. ncbi request reprint A screening assessment of cognitive impairment in patients with ALS
    Paul H Gordon
    Departmen of Neurology, Columbia University, New York, USA
    Amyotroph Lateral Scler 8:362-5. 2007
    ..Behavioral and motor impairment is associated with depressive symptoms in caregivers. Studies with formal neuropsychological tests are needed to determine the sensitivity and specificity of the screen in ALS...
  15. doi request reprint Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study
    Judith G Rabkin
    Department of Psychiatry, Columbia University, New York, New York, USA
    Muscle Nerve 39:297-303. 2009
    ..The number needed to treat was 1.6 (ITT). No medically serious adverse events were reported. Modafinil may be a promising intervention for fatigue in ALS patients. Replication in a larger study is needed...
  16. ncbi request reprint ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): Study methodology, recruitment, and baseline demographic and disease characteristics
    Hiroshi Mitsumoto
    Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, Columbia University Medical Center, New York
    Amyotroph Lateral Scler Frontotemporal Degener 15:192-203. 2014
    ..The baseline demographic and disease features of the study sample are now fully characterized. ..
  17. ncbi request reprint The Timed Up and Go test: predicting falls in ALS
    Jacqueline Montes
    Department of Neurology, College of Physicians and Surgeons, The Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
    Amyotroph Lateral Scler 8:292-5. 2007
    ..The TUG test can guide management of patients with ALS; a time of 14 s can be used to prompt the recommendation for mobility aids to prevent falls...
  18. ncbi request reprint Amyotrophic lateral sclerosis and primary lateral sclerosis: evidence-based diagnostic evaluation of the upper motor neuron
    Stephen Chan
    Department of Radiology, Columbia University, New York Presbyterian Hospital, Milstein Hospital Building, 3rd Floor, 177 Fort Washington Avenue, New York, NY 10032, USA
    Neuroimaging Clin N Am 13:307-26. 2003
    ..Newer MR tools, such as diffusion tensor imaging, magnetization transfer imaging, and functional MR imaging, have substantial promise as scientific and clinical tools in this ongoing endeavor...
  19. doi request reprint Amyotrophic lateral sclerosis with ragged-red fibers
    Michio Hirano
    Department of Neurology, Columbia University Medical Center, 3 317 Russ Berrie Medical Science Pavilion, 1150 St Nicholas Ave, New York, NY 10032, USA
    Arch Neurol 65:403-6. 2008
    ..Motor neuron diseases (amyotrophic lateral sclerosis [ALS] and spinal muscular atrophy [SMA]) have been rarely associated with mitochondrial respiratory chain defects...
  20. ncbi request reprint Sporadic amyotrophic lateral sclerosis and breast cancer: Hyaline conglomerate inclusions lead to identification of SOD1 mutation
    Arthur P Hays
    Department of Pathology Neuropathology, Columbia University Medical Center, PH15th Stem, Room 124, 630 West 168th Street, New York, NY 10032, USA
    J Neurol Sci 242:67-9. 2006
    ..These features suggested a mutation of SOD1 mutation although no other family members were affected. DNA analysis of autopsy tissue indicated an I113T SOD1 mutation...
  21. ncbi request reprint Predictors and course of elective long-term mechanical ventilation: A prospective study of ALS patients
    Judith G Rabkin
    Department of Psychiatry, Columbia University Medical Center, and New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
    Amyotroph Lateral Scler 7:86-95. 2006
    ..ALS clinicians will need to recognize this motivation and provide appropriate clinical education to both patient and family...
  22. ncbi request reprint Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial
    Petra Kaufmann
    Department of Neurology, The Eleanor and Lou Gehrig MDA ALS Research Center, College of Physicians and Surgeons, New York, NY, USA
    Amyotroph Lateral Scler 8:42-6. 2007
    ..97 (95% CI 0.93-0.98). We conclude that the ALSFRS-R shows excellent inter- and intra-rater reliability, and reliability of telephone administration when used as primary outcome measure in a multicenter ALS trial...
  23. pmc Amyotrophic lateral sclerosis and neurosarcoidosis: a case report
    I Hweii Amy Chen
    Department of Neurology and the Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, New York, USA
    Muscle Nerve 39:234-8. 2009
    ..The targeting of the motor neurons by the sarcoid inflammation raises questions regarding the role of cellular immunity in the pathomechanisms for ALS...
  24. pmc Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III
    Petra Kaufmann
    Department of Neurology, Clinical Coordinating Center, Columbia University, New York, NY 10032, USA
    Ann Neurol 66:235-44. 2009
    ..Our aims were to choose between two high doses of CoQ10 for ALS, and to determine if it merits testing in a Phase III clinical trial...
  25. ncbi request reprint A pathogenic peripherin gene mutation in a patient with amyotrophic lateral sclerosis
    Conrad L Leung
    Departments of Pathology, College of Physicians and Surgeons, Columbia University, NewYork, NY 10032, USA
    Brain Pathol 14:290-6. 2004
    ..Moreover, the neurofilament light (NF-L) protein was not able to rescue the mutant protein from forming aggregates. These data imply that mutation of PRPH is a contributing factor for ALS...
  26. doi request reprint Experience with the Awaji Island modifications to the ALS diagnostic criteria
    Amy Chen
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Muscle Nerve 42:831-2. 2010
    ....
  27. pmc Study of 962 patients indicates progressive muscular atrophy is a form of ALS
    W K Kim
    The Eleanor and Lou Gehrig MDA ALS Research Center, The Neurological Institute of New York, Columbia University Medical Center, New York, NY 10032, USA
    Neurology 73:1686-92. 2009
    ..Whether PMA is actually a form of ALS has important consequences clinically and for therapeutic trials. We compared the survival of patients with PMA or ALS to analyze the clinical features that influence survival in PMA...
  28. ncbi request reprint High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial
    D J Lange
    Department of Neurology, Mt Sinai School of Medicine, One Gustave L Levy Place, Box 1052, New York, NY 10029, USA
    Neurology 67:991-7. 2006
    ..To evaluate changes in respiratory function in patients with ALS after using high-frequency chest wall oscillation (HFCWO)...
  29. ncbi request reprint Japanese and American ALS patient preferences regarding TIV (tracheostomy with invasive ventilation): A cross-national survey
    Judith Rabkin
    New York State Psychiatric Institute and Department of Psychiatry, Columbia University, New York, USA
    Amyotroph Lateral Scler Frontotemporal Degener 15:185-91. 2014
    ..In conclusion, factors other than patient preferences, such as neurologist preferences, caregiver attitudes and perhaps lack of advance planning, may influence probability of TIV utilization. ..
  30. pmc Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD)
    Emanuele D'Amico
    Eleanor and Lou Gehrig MDA ALS Center, Columbia University Medical Center, 710 West 168th Street, New York, NY 10032, USA
    Muscle Nerve 47:28-32. 2013
    ..We know little about its early stages, but such knowledge would help to identify the mechanisms underlying PLS and ALS and determine why PLS patients seem to be protected against lower MND (LMND)...
  31. ncbi request reprint Palliative care for patients with amyotrophic lateral sclerosis: "prepare for the worst and hope for the best"
    Hiroshi Mitsumoto
    Eleanor and Lou Gehrig ALS MDA Center, College of Physicians and Surgeons, Columbia University, Neurological Institute, New York, NY 10032, USA
    JAMA 298:207-16. 2007
    ....
  32. ncbi request reprint Randomized control trials in ALS: lessons learned
    Hiroshi Mitsumoto
    The Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University Medical Center, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:8-13. 2004
  33. doi request reprint Senataxin mutations and amyotrophic lateral sclerosis
    Michio Hirano
    Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA
    Amyotroph Lateral Scler 12:223-7. 2011
    ..Screening for SETX mutations should be considered in patients with apparently sporadic juvenile-onset ALS, hereditary motor neuropathy, and overlap syndromes with ataxia and motor neuron disease...
  34. ncbi request reprint A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS
    G Levy
    Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    Neurology 66:660-3. 2006
    ..The combination of a small pool of patients at any given time with the availability of many potential neuroprotective agents to be tested in ALS requires efficient phase II trial designs...
  35. ncbi request reprint 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla
    E P Pioro
    Department of Neurology and Neurosciences, The Cleveland Clinic Foundation, OH 44195, USA
    Neurology 53:71-9. 1999
    ....
  36. ncbi request reprint The ALSFRSr predicts survival time in an ALS clinic population
    P Kaufmann
    Department of Neurology, College of Physicians and Surgeons, The Neurologic Institute, Columbia University, 710 W 168th Street, New York, NY 10032, USA
    Neurology 64:38-43. 2005
    ..To determine whether the Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRSr), a predictor of survival time in ALS clinical trials, predicts survival time in an ALS clinic population...
  37. pmc Prevalence of depressive disorders and change over time in late-stage ALS
    J G Rabkin
    New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA
    Neurology 65:62-7. 2005
    ....
  38. ncbi request reprint Quantitative objective markers for upper and lower motor neuron dysfunction in ALS
    H Mitsumoto
    Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
    Neurology 68:1402-10. 2007
    ..To investigate the value of objective biomarkers for upper (UMN) and lower (LMN) motor neuron involvement in ALS...
  39. ncbi request reprint Incidence and predictors of PEG placement in ALS/MND
    S M Albert
    Eleanor and Lou Gehrig MDA ALS Center, Neurological Institute, Columbia University, New York, NY, USA
    J Neurol Sci 191:115-9. 2001
    ..3% of those "absolutely against" (p<0.01). PEG users were more likely to have initiated health care proxies. These findings suggest that patients who use PEG may be consistently proactive in the face of the disease...
  40. ncbi request reprint Neuronal pathology in the wobbler mouse brain revealed by in vivo proton magnetic resonance spectroscopy and immunocytochemistry
    E P Pioro
    Department of Neurology, The Cleveland Clinic Foundation, OH 44195, USA
    Neuroreport 9:3041-6. 1998
    ..In vivo IH-MRS and correlative postmortem study of wobbler mouse brain will allow temporal monitoring of neuronal degeneration and responsiveness to neuroprotective pharmacotherapies...
  41. pmc Wish to die in end-stage ALS
    S M Albert
    The Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, Columbia University, New York, NY 10032, USA
    Neurology 65:68-74. 2005
    ..In retrospective studies, estimates of hastened dying among seriously ill patients range from <2% in one national survey to as much as 20% in end-stage disease cohorts...
  42. ncbi request reprint Transcranial magnetic stimulation for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS)
    H Mitsumoto
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Suppl Clin Neurophysiol 59:327-32. 2006
  43. doi request reprint Prevalence of fatigue and depression in ALS patients and change over time
    M C McElhiney
    New York State Psychiatric Institute, Unit 51, New York, NY 10032, USA
    J Neurol Neurosurg Psychiatry 80:1146-9. 2009
    ..Amyotrophic lateral sclerosis (ALS) patients report both fatigue and depression. It is not clear how frequently each occurs, to what extent they occur together, how each relates to ALS disease status, or their stability over time...
  44. ncbi request reprint Development and evaluation of a self-administered version of the ALSFRS-R
    J Montes
    Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10032
    Neurology 67:1294-6. 2006
    ..The self-administered ALSFRS-R showed excellent reliability (intraclass correlation = 0.93, 95% CI: 088 to 0.96) and similar sensitivity to change over time vs the standard evaluator-administered ALSFRS-R...
  45. ncbi request reprint Identification of a novel mutation in Cu/Zn superoxide dismutase gene associated with familial amyotrophic lateral sclerosis
    A Naini
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Neurol Sci 198:17-9. 2002
    ..The enzymatic activity of mutated SOD-1 measured in erythrocyte lysate was 70% of control. This heterozygote mutation, which is associated with the late onset of the disease, is located in the active site of the enzyme...
  46. ncbi request reprint Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS)
    P Kaufmann
    Eleanor and Lou Gehrig MDA ALS Research Center, Neurologic Institute, Department of Neurology, Columbia University, New York 10032, USA
    Neurology 62:1753-7. 2004
    ..To develop objective markers for upper motor neuron (UMN) involvement in ALS, the value of single-voxel MR spectroscopy (MRS) and transcranial magnetic stimulation (TMS) was studied...
  47. ncbi request reprint The natural history of primary lateral sclerosis
    P H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Neurology 66:647-53. 2006
    ....
  48. ncbi request reprint Randomized controlled phase II trial of glatiramer acetate in ALS
    P H Gordon
    Department of Neurology, Columbia University, NY, USA
    Neurology 66:1117-9. 2006
    ..01). Treated patients showed enhanced lymphocyte proliferation (p = 0.02). The safety profile and immune effects support conducting larger trials of dose selection and efficacy...
  49. ncbi request reprint Necroptosis drives motor neuron death in models of both sporadic and familial ALS
    Diane B Re
    Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA
    Neuron 81:1001-8. 2014
    ..The necroptotic pathway therefore constitutes a potential therapeutic target for this incurable disease. ..
  50. doi request reprint Tracheostomy with invasive ventilation for ALS patients: neurologists' roles in the US and Japan
    Judith Rabkin
    New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
    Amyotroph Lateral Scler Frontotemporal Degener 14:116-23. 2013
    ..While Americans seldom recommended TIV to patients and most would not choose TIV for themselves, Japanese neurologists' recommendations and personal choices diverged...
  51. ncbi request reprint Biochemical markers: con
    Hiroshi Mitsumoto
    Eleanor and Lou Gehrig MDA ALS Center, Columbia University, New York, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 3:S83. 2002
  52. ncbi request reprint Methionine-free brain-derived neurotrophic factor in wobbler mouse motor neuron disease: dose-related effects and comparison with the methionyl form
    Takeo Ishiyama
    Department of Neurology and Neuroscience, The Cleveland Clinic Foundation, Cleveland, OH, USA
    Brain Res 944:195-9. 2002
    ..At 5 mg/kg, the beneficial effect was more modest. Plasma BDNF levels after the final injection were dose-dependent and did not differ between BDNF groups. Endogenous met-free BDNF exerts effects similar to met-BDNF in wobbler MND...
  53. ncbi request reprint Olfactory ensheathing glia injections in Beijing: misleading patients with ALS
    Sheena Chew
    Department of Neurology, Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
    Amyotroph Lateral Scler 8:314-6. 2007
    ..Clinics that give experimental and potentially harmful treatments outside the construct of well-designed clinical trials put patients at risk and do a disservice to the ALS community...
  54. ncbi request reprint An observational study of cognitive impairment in amyotrophic lateral sclerosis
    Gregory A Rippon
    Department of Neurology, Gertrude H Sergievsky Center, Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Eleanor and Lou Gehrig MDA ALS Research Center, New York, NY, USA
    Arch Neurol 63:345-52. 2006
    ..Clinical and pathologic features overlap in frontotemporal lobar dementia and ALS. Demographics, respiratory status, bulbar site of onset, and disease severity are potential risk factors for cognitive impairment in ALS...
  55. ncbi request reprint A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS
    S N Scelsa
    Beth Israel Medical Center, New York, NY, USA
    Neurology 64:1298-300. 2005
    ..36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS...
  56. pmc Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis
    Emanuele D'Amico
    Eleanor and Lou Gehrig MDA ALS Research Center, The Neurological Institute of New York, Columbia University Medical Center, New York, NY 10032, USA
    Free Radic Biol Med 65:509-27. 2013
    ....
  57. doi request reprint Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes
    Rebecca M Wolf Gilbert
    Department of Neurology, NYU Langone Medical Center, New York, New York 10016, USA
    Mov Disord 25:1868-75. 2010
    ..Having MND may be a risk factor for parkinsonism. A prospective study may elucidate this possibility...
  58. ncbi request reprint Recent advances in amyotrophic lateral sclerosis research
    Serge Przedborski
    Department of Neurology, Columbia University College of Physicians and Surgeons, 650 West 168th Street, BB 307, New York, NY 10032, USA
    Curr Neurol Neurosci Rep 3:70-7. 2003
    ....
  59. doi request reprint The role of exercise in amyotrophic lateral sclerosis
    Amy Chen
    Department of Neurology, Columbia University, 710 West 168th Street, 9th Floor, New York, NY 10032, USA
    Phys Med Rehabil Clin N Am 19:545-57, ix-x. 2008
    ..In this article, the authors review the literature on the role of exercise in patients who have ALS, and briefly compare what is known about exercise in other neuromuscular diseases...
  60. doi request reprint Research advances in amyotrophic lateral sclerosis, 2009 to 2010
    Rebecca Traub
    Eleanor and Lou Gehrig MDA ALS Research Center, Neurological Institute, Columbia University Medical Center, 710 West 168th Street, New York, NY 10032, USA
    Curr Neurol Neurosci Rep 11:67-77. 2011
    ..With greater understanding of ALS pathogenesis and exciting new therapeutic technologies, there is hope for future progress in treating this disease...
  61. ncbi request reprint Role of brain-derived neurotrophic factor in wobbler mouse motor neuron disease
    K Tsuzaka
    Department of Neurology and Neurosciences, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Muscle Nerve 24:474-80. 2001
    ..Our study indicates that BDNF is important in halting nitric oxide (NO)-mediated motor neuron degeneration, which has potential implications for the treatment of neurodegenerative disorders...
  62. doi request reprint Web-based data management for a phase II clinical trial in ALS
    Richard Buchsbaum
    Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
    Amyotroph Lateral Scler 10:374-7. 2009
    ..Given sufficient resources, a comprehensive web-based data management system can meet the need for clean, available data in clinical trials in ALS and similar diseases, and can contribute significantly to their efficient execution...
  63. ncbi request reprint Amyotrophic lateral sclerosis
    Paul H Gordon
    Eleanor and Lou Gehrig Muscular Dystrophy Association Amyotrophic Lateral Sclerosis Research Center, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Sci Aging Knowledge Environ 2003:dn2. 2003
    ..Cognition, the extraocular muscles, and the urinary sphincters were spared. Respiratory muscle weakness was a late manifestation...
  64. ncbi request reprint Differential susceptibility of the ocular motor system to disease
    Henry J Kaminski
    Department of Neurology, Case Western Reserve University, University Hospital of Cleveland, Cleveland, Ohio 44106, USA
    Ann N Y Acad Sci 956:42-54. 2002
    ..It is hoped that this review will encourage others to view the world of neuromuscular diseases as delineated into those that spare the ocular motor system and those that do not...
  65. ncbi request reprint Caregiver assessment: summary
    Hiroshi Mitsumoto
    Eleanor and Lou Gehrig MDA ALS Center, Columbia University, New York, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 3:S31-4. 2002
  66. ncbi request reprint Amyotrophic lateral sclerosis: objective upper motor neuron markers
    Petra Kaufmann
    Neurological Institute, 9th Floor, 710 West 168th Street, New York, NY 10032, USA
    Curr Neurol Neurosci Rep 2:55-60. 2002
    ..This article reviews the progress that has been made over the past two decades towards establishing valid diagnostic and natural history markers of upper motor neuron involvement in ALS...
  67. ncbi request reprint [A strategy to develop effective ALS therapy]
    Hiroshi Mitsumoto
    Eleanor and Lou Gehrig MDA ALS Research Center, Neurological Institute, Columbia University, 710 West 168th Street, New York, NY 10032, USA
    Brain Nerve 59:383-91. 2007
    ....
  68. ncbi request reprint [Management and care for patients with ALS]
    Hiroshi Mitsumoto
    Eleanor and Lou Gehrig MDA ALS Research Center, Neurological Institute, Columbia University, USA
    Rinsho Shinkeigaku 46:828-31. 2006
    ..Undoubtedly, we are in the midst of incredible progress in ALS...
  69. pmc Transcranial magnetic stimulation in ALS: utility of central motor conduction tests
    A G Floyd
    Clinical Motor Physiology Laboratory, Department of Neurology, Columbia University Medical Center, New York, NY, USA
    Neurology 72:498-504. 2009
    ..To investigate transcranial magnetic stimulation (TMS) measures as clinical correlates and longitudinal markers of amyotrophic lateral sclerosis (ALS)...
  70. doi request reprint Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
    Erik P Pioro
    Section of ALS and Related Disorders, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Ann Neurol 68:693-702. 2010
    ..To evaluate dextromethorphan combined with ultra low-dose quinidine (DMq) for treating pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS)...
  71. ncbi request reprint Development, analysis, refinement, and utility of an interdisciplinary amyotrophic lateral sclerosis database
    V Dal Bello-Haas
    Department of Neurology, The Cleveland Clinic Foundation, OH 44195, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 2:39-46. 2001
    ..Ongoing refinement will ensure that this HCP-driven ALS database continues to be informative, practical and effective for decision-making and enhancing delivery of care...
  72. ncbi request reprint Clinical trials: present and future
    H Mitsumoto
    Eleanor and Lou Gehrig MDA/ALS Center, Columbia-Presbyterian Medical Center, New York, NY, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 2:S10-4. 2001
    ..Effort must also be directed towards the search for objective markers for ALS...
  73. ncbi request reprint Use of palatal lift and palatal augmentation prostheses to improve dysarthria in patients with amyotrophic lateral sclerosis: a case series
    S J Esposito
    Department of Dentistry, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Prosthet Dent 83:90-8. 2000
    ..The use of palatal lift/augmentation prostheses for dysarthria in ALS is not a frequently requested procedure by neurologists...
  74. ncbi request reprint Whole-genome analysis of sporadic amyotrophic lateral sclerosis
    Travis Dunckley
    Translational Genomics Research Inst, Phoenix, AZ 85004, USA
    N Engl J Med 357:775-88. 2007
    ..Approximately 90% of persons with amyotrophic lateral sclerosis (ALS) have the sporadic form, which may be caused by the interaction of multiple environmental factors and previously unknown genes...
  75. ncbi request reprint Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients
    R Lee Mosley
    Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE 68198 5800, USA
    Amyotroph Lateral Scler 8:235-42. 2007
    ..These data show significant humoral responses and cytokine trends following GA immunization in ALS patients...
  76. ncbi request reprint Clinical care of patients with amyotrophic lateral sclerosis
    Aleksandar Radunović
    MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, PO 41, Institute of Psychiatry, King s College London, London, UK
    Lancet Neurol 6:913-25. 2007
    ..We recommend that the plethora of evidence-based guidelines should be compiled into an internationally agreed guideline of best practice...
  77. pmc Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis
    Nicola J Rutherford
    Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America
    PLoS Genet 4:e1000193. 2008
    ....
  78. doi request reprint Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons
    John T Dimos
    Harvard Stem Cell Institute, Stowers Medical Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA
    Science 321:1218-21. 2008
    ..These patient-specific iPS cells possess properties of embryonic stem cells and were successfully directed to differentiate into motor neurons, the cell type destroyed in ALS...
  79. ncbi request reprint Measures of dyspnea in patients with amyotrophic lateral sclerosis
    Noah Lechtzin
    Department of Medicine, Division of Pulmonary and Critical Care, Johns Hopkins University School of Medicine, 1830 E Monument Street, 5th Floor, Baltimore, Maryland 21205, USA
    Muscle Nerve 35:98-102. 2007
    ..The BDI and TDI thus appear to be useful measures in ALS and may have both clinical and research applications...
  80. pmc Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery
    Katrina Gwinn
    National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 2:e1254. 2007
    ..This resource should facilitate genetic discoveries which we anticipate will ultimately provide a better understanding of the biological mechanisms of neurodegeneration in ALS...
  81. doi request reprint Electrodiagnostic criteria for diagnosis of ALS
    Mamede de Carvalho
    Department of Neurology, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal
    Clin Neurophysiol 119:497-503. 2008
    ..Methods for detection of upper motor neuron abnormality appear sensitive but require further study, particularly regarding their value when clinical signs of upper motor neuron lesion are uncertain...
  82. ncbi request reprint ALS Research Group (ALSRG): second meeting, a summary report
    Petra Kaufmann
    Amyotroph Lateral Scler 7:252-5. 2006
  83. ncbi request reprint Drug therapy in amyotrophic lateral sclerosis
    Brian Murray
    Institute of Molecular Medicine, Trinity Center for Health Sciences, Dublin 8, Ireland
    Adv Neurol 88:63-82. 2002
  84. ncbi request reprint Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia
    Xiaohong Li
    Department of Neurology, Pritzker School of Medicine and Center for Comprehensive Care and Research on Memory Disorders, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Ann Neurol 58:858-64. 2005
    ..However, the strong association between heterozygosity and PPA raises new questions about its cause and the role of PrP in other neurodegenerative diseases...
  85. ncbi request reprint Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease
    Takeo Ishiyama
    Sumitomo Pharmaceuticals Research Division, 1 98 Kasugadenaka 3 chome, Konohanaku, Osaka 554 0022, Japan
    Brain Res 1019:226-36. 2004
    ....
  86. ncbi request reprint Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial
    P Nigel Leigh
    Department of Neurology, Institute of Psychiatry, London, UK
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:84-98. 2004
    ....

Research Grants7

  1. Diagnostic and Natural History Markers in ALS
    Hiroshi Mitsumoto; Fiscal Year: 2001
    ..abstract_text> ..
  2. Diagnostic and Natural History Markers in ALS
    Hiroshi Mitsumoto; Fiscal Year: 2002
    ..abstract_text> ..
  3. Diagnostic and Natural History Markers in ALS
    Hiroshi Mitsumoto; Fiscal Year: 2003
    ..abstract_text> ..
  4. A Scientific Meeting of ALS Clinical Trials
    Hiroshi Mitsumoto; Fiscal Year: 2003
    ..abstract_text> ..
  5. Multicenter ALS Cohort Study of Oxidative Stress and Disease Progression
    Hiroshi Mitsumoto; Fiscal Year: 2009
    ..Our study will increase the understanding of the disease mechanisms involved in disease prognosis and may be the first step toward new treatment and prevention approaches, such as multiple anti-oxidant therapy, to target OS in ALS. ..
  6. Multicenter ALS Cohort Study of Oxidative Stress and Disease Progression
    Hiroshi Mitsumoto; Fiscal Year: 2010
    ..Our study will increase the understanding of the disease mechanisms involved in disease prognosis and may be the first step toward new treatment and prevention approaches, such as multiple anti-oxidant therapy, to target OS in ALS. ..
  7. Multicenter ALS Cohort Study of Oxidative Stress and Disease Progression
    Hiroshi Mitsumoto; Fiscal Year: 2010
    ..Our study will increase the understanding of the disease mechanisms involved in disease prognosis and may be the first step toward new treatment and prevention approaches, such as multiple anti-oxidant therapy, to target OS in ALS. ..